Table 1 Biologic agents under consideration for the treatment of Psoriatic arthritis
From: Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment
| Suppression of inflammatory mediators | ||
| target | agent | comment |
| IL-1 | Anakinra | IL-1 receptor antagonist |
| IL-8 | ABXIL-8 | human anti-IL-8 mAb |
| Modulation of the function of Anti-inflammatory mediators | ||
| target | agent | comment |
| IL-10 | rIL-10 | recombinant human Th2 cytokine |
| IL-11 | rIL-11 | recombinant human Th2 cytokine |
| Alteration of T cell number and function interaction | ||
| target | agent | comment |
| IL-12 | anti-IL-12 mAb | several in development |
| CD25 (IL-2 receptor) | Daclizumab | humanized anti-CD25 mAb |
| CD2 | Alefacept | human LFA-3/IgG fusion protein |
| CD11a (LFA-1) | Efalizumab | humanized anti-CD11a mAb |
| TCR/CD3 | huOKT3γ1(ala-ala) | humanized anti-CD3 mAb |
| CD80/CD86 | IDEC-114 | humanized anti-CD80 mAb |
| CTLA4Ig | fusion protein of CTLA-4/Ig | |
| CD40/CD40L | IDEC-131 | humanized anti-CD154 mAb |